Short Term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor Positive Breast Cancers

PURPOSE: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have improved progression free survival for metastatic, estrogen receptor positive (ER+) breast cancers, but their role in the non-metastatic setting remains unclear. We sought to understand the effects of CDK4/6 inhibition (CDK4/6i) and radia...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Pesch, Andrea M., Hirsh, Nicole H., Chandler, Benjamin C., Michmerhuizen, Anna R., Ritter, Cassandra L., Androsiglio, Marlie P., Wilder-Romans, Kari, Liu, Meilan, Gersch, Christina L., Larios, José M., Pierce, Lori J., Rae, James M., Speers, Corey W.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7744368/
https://ncbi.nlm.nih.gov/pubmed/32967938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-2269
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky